I Agree

We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms of Use.

PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Mereo BioPharma Grp (MPH)

Mereo BioPharma Grp

PDMR Notification
RNS Number : 8751O
Mereo BioPharma Group plc
04 October 2019
 

Mereo BioPharma Group plc

 

 ("Mereo" or the "Company")

 

Notification of PDMR Dealing

 

London, October 04, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on October 03, 2019, Alastair MacKinnon, Chief Medical Officer of Mereo, purchased 8383 Ordinary Shares at a price of GBP0.60 per share. On the same day, Alastair also purchased 8391 Ordinary Shares at a price of GBP0.59 per share.

 

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows.

 

1

Details of the person discharging managerial responsibilities

a)

Name

Alastair MacKinnon

2

Reason for the notification

a)

Position/status

Chief Medical Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

MEREO BIOPHARMA GROUP PLC ORDINARY SHARES

 

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

GBP0.60

8383

 

 

d)

Aggregated information: volume, Price

Aggregated volume: 8383

Aggregated price: GBP0.60

e)

Date of the transaction

2019-10-03

f)

Place of the transaction

AIMX

 

 

 

1

Details of the person discharging managerial responsibilities

a)

Name

Alastair MacKinnon

2

Reason for the notification

a)

Position/status

Chief Medical Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

MEREO BIOPHARMA GROUP PLC ORDINARY SHARES

 

b)

Nature of the transaction

AIMX

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

GBP0.59

8391

 

 

d)

Aggregated information: volume, Price

Aggregated volume: 8391

Aggregated price: GBP0.59

e)

Date of the transaction

2019-10-03

f)

Place of the transaction

AIMX

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBXBDGUUGBGCS
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close